Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Gianpaolo Bravi

Keith Biggadike

Diane Mary Coe

Pritom Shah

Gordon G Weingarten

Graham George Adam Inglis

Deborah Needham

Peter D Howes

Daniel Terence Tape

Heather Hobbs

Simon Peace

Charles David Hartley

Aurelie Cecile Champigny

David Haigh

Deborah Lynette Jackson

Martin John Slater

Victoria Lucy Helen Lovegrove

Katrina Jane Wareing

Simon Nicolle

Rossella Guidetti

The invention relates to compounds of formula (I): wherein R, R, R, R, L and A are as defined in the description and claims, or pharmaceutically acceptable salts thereof having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions including a compound of formula (I) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.

Chemical compounds

A compound of formula (I) wherein or a pharmaceutically acceptable salt thereof.

N-cyclobutyl-imidazopyridine-methylamine as TRPV1 antagonists

Novel anti-viral agents of Formula wherein:

4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as HCV inhibitors

The invention provides the compounds of formula (I) or a pharmaceutically acceptable salt thereof. Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever and inflammation of a variety of conditions and diseases.

Pyrimidine derivative as selective COX-2 inhibitors

Growing community of inventors

Stevenage, United Kingdom

Gianpaolo Bravi